Articles

데일리팜 리크루트: Vyloy Access Watch

Vyloy (zolbetuximab) has passed the HIRA Pharmacoeconomic Evaluation Subcommittee and is set for Drug Reimbursement Evaluation Committee review. This analysis covers the clinical evidence, regulatory milestones, and strategic implications for pharma stakeholders.

Florian Lordick Elected ESMO President 2029-2030

Professor Florian Lordick has been elected President of the European Society for Medical Oncology (ESMO) for the 2029–2030 term. This analysis outlines the timeline, Lordick's background, and strategic implications for pharma teams tracking ESMO's evolving priorities.

Pharmaceuticals Europe: Approval to Access Gap

Despite EMA approvals, patients across Europe face delayed or no access to new medicines. This analysis examines the systemic barriers, the EU Pharma Package response, and the strategic implications for European pharma companies and investors.

Lilly Spotlight Growing Hematology Portfolio at EHA

Lilly will present positive Phase 3 BRUIN CLL-322 results at the 2026 EHA Annual Meeting, comparing pirtobrutinib plus venetoclax and rituximab against venetoclax and rituximab. The presentation underscores Lilly's expanding hematology portfolio, bolstered by recent acquisitions of Ajax Therapeutics and Kelonia Therapeutics.

BBIA Official Website Context: EuropaBio Join

The Bio-based and Biodegradable Industries Association (BBIA) has joined EuropaBio, Europe's largest biotechnology industry group. This move strengthens advocacy for the industrial bioeconomy, with implications for pharma companies investing in bio-based materials and sustainable packaging.

Kaléo's Initiative on Allergy Awareness: Amplifying Patient Stories

Kaléo's sponsorship of the 'May Contain' docudrama marks a strategic shift toward patient storytelling in allergy awareness. This analysis covers the initiative, regulatory context, and competitive implications for pharma teams.

Pharma People on the Move: Spring 2026 Roundup — Regulatory Updates

Spring 2026 brings notable pharma executive moves and EMA regulatory updates. This roundup analyzes key appointments, the evolving drug approval process in Europe, and what BD teams and investors should watch next.

Cellectar Biosciences (CLRB) FDA Approvals, PDUFA Dates & Drug Alerts 2026

Cellectar Biosciences (CLRB) has not received FDA approval in the past two years but has drugs under review, including iopofosine I 131 with Breakthrough Therapy designation. The company is eligible for a Pediatric Review Voucher upon approval, and key PDUFA dates in 2026 will be critical for investors and BD teams.

Circulating Biomarkers: Additional Evidence Supporting Their Clinical Use in Breast Cancer

Recent studies provide additional evidence supporting the clinical use of circulating biomarkers in breast cancer, including circulating tumor cells and ctDNA. This analysis reviews the key findings and their implications for pharma teams, investors, and analysts.

Tracy Beth Høeg's Departure: Implications for Pharma BD and Regulatory Teams

Tracy Beth Høeg's reported departure from the FDA's Center for Drug Evaluation and Research (CDER) signals potential shifts in regulatory oversight. Pharmaceutical companies and investors should prepare for evolving approval processes and strategic considerations.

AbbVie Plans Layoffs: Implications for the Pharma Industry

Structured plan for AbbVie Plans Layoffs: Implications for the Pharma Industry

Favipiravir Shipped for Europe Hantavirus Response

Experimental antiviral favipiravir has been shipped to Europe for hantavirus patients and clinical trials, marking a significant step in preparedness. Meanwhile, US passengers exposed to the virus are offered home quarantine with strict monitoring.

Cynata Therapeutics (ASX:CYP) Surges on European Regulatory Milestone for CYP-001

Cynata Therapeutics (ASX:CYP) shares experienced a notable increase following the European Medicines Agency's Paediatric Committee (PDCO) granting a Positive Opinion for the Paediatric Investigation Plan (PIP) concerning CYP-001. This development marks a significant step forward for the company's regenerative medicine candidate in Europe.

EMA's United for Health Initiative at WorldPride 2026

The European Medicines Agency (EMA) will participate in WorldPride 2026 in Amsterdam, marching under the banner "United for Health". This initiative underscores EMA's commitment to diversity, equity, and public health on a global stage.

CinnaGen's Zandoriah Achieves EU Approval for Osteoporosis Treatment

CinnaGen has achieved a landmark victory with the European Commission's approval of its osteoporosis drug, Zandoriah (teriparatide). This historic first for an Iranian pharmaceutical company opens new avenues for international market access and highlights the growing capabilities within Iran's biotech sector.

SFEE Highlights Significant Delays in Greek Patient Access to New Medicines

The Association of Pharmaceutical Companies of Greece (SFEE) has raised alarms regarding substantial delays in bringing new, innovative medicines to Greek patients, with access often occurring nearly two years after European Medicines Agency (EMA) approval. This situation poses significant challenges for patient care and the pharmaceutical market in Greece.

Medscape Education Leverages AI for Hematology at EHA 2026

Medscape Education will host a session on the practical and ethical use of AI in Hematology and Oncology at EHA 2026. This initiative aims to equip hematologists with the knowledge to navigate the evolving landscape of AI in their specialty.

OS Therapies' OST-HER2 Trial Hits 2.5-Year Survival Milestone in Osteosarcoma

OS Therapies has achieved a statistically significant 2.5-year overall survival rate of 75% in its Phase 2b trial of OST-HER2 for fully resected pulmonary metastatic osteosarcoma. This result compares favorably to a pooled historical control of 47%.

Quoin Pharmaceuticals Aims for First Peeling Skin Syndrome Trial with FDA IND Submission

Quoin Pharmaceuticals has submitted the first Investigational New Drug (IND) application to the FDA for QRX003, marking a potential first-ever clinical trial for Peeling Skin Syndrome (PSS). This move signifies a critical step towards addressing a disease with no existing treatment options.

Oxurion NV Expands GLP-1 and Peptide Research Services Amidst Market Growth

Oxurion NV has announced an expansion of its clinical research services, specifically targeting the rapidly growing demand for GLP-1 and peptide therapeutics. This strategic move aligns with significant market trends and increasing clinical trial activity in these therapeutic areas.